Study guide
2.3 Cardiac Transplant
AACN CCRN Pediatric Critical Care Certification Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Fees & Renewal 1.3 Test Plan & Study Strategy
2 Cardiovascular I — Structure & Procedures
2.1 Cardiac Malformations 2.2 Cardiac Surgery & Catheterization 2.3 Cardiac Transplant
3 Cardiovascular II — Hemodynamics
3.1 Cardiogenic Shock 3.2 Heart Failure & Cardiomyopathies 3.3 Inflammatory Disease, Hypertensive Crisis & Vascular Occlusions
4 Cardiovascular III — Rhythm
4.1 Pediatric Dysrhythmias 4.2 Conduction System Defects
5 Respiratory I — Acute Failure
5.1 ARDS & Acute Respiratory Failure 5.2 Pulmonary Embolus & Acute Respiratory Infection 5.3 Chronic Respiratory Failure & Pulmonary Conditions
6 Respiratory II — Specialty Airway
6.1 Airway Malformations & Status Asthmaticus 6.2 Pulmonary Hypertension 6.3 Thoracic & Airway Trauma and Thoracic Surgery
7 Endocrine Emergencies
7.1 Diabetes Mellitus & DKA 7.2 Hyperglycemia & Hypoglycemia 7.3 DI, SIADH & Cerebral Salt Wasting
8 Hematology & Immunology
8.1 Sickle Cell Crisis 8.2 Coagulopathies, Myelosuppression & Oncologic Complications 8.3 Transfusion Reactions, Immune Deficiencies, Anemia & BMT
9 Gastrointestinal
9.1 Congenital GI Abnormalities & NEC 9.2 GI Hemorrhage, Abdominal Trauma & Peritonitis 9.3 Hepatic Failure, Malnutrition & GI Surgery
10 Renal/GU & Integumentary
10.1 AKI, CKD & Life-Threatening Electrolytes 10.2 HUS & Kidney Transplant 10.3 Integumentary Injuries
11 Neurological I — Acute Brain Injury
11.1 Traumatic Brain Injury & Intracranial Hemorrhage 11.2 Seizure Disorders, Encephalopathy & Delirium 11.3 Hydrocephalus & Congenital Neurological Abnormalities
12 Neurological II, Musculoskeletal & Behavioral
12.1 Neuro Infection, Neuromuscular Disorders & Neurosurgery 12.2 Stroke, Brain Death & Space-Occupying Lesions 12.3 Musculoskeletal Critical Care 12.4 Behavioral & Psychosocial Care
13 Multisystem I — Shock & Inflammation
13.1 Sepsis & SIRS 13.2 Shock States & MODS 13.3 Acid-Base, Pain & Healthcare-Acquired Conditions
14 Multisystem II — Crisis & Goals of Care
14.1 Burns & Thermal Injury 14.2 Submersion Injury 14.3 Toxic Ingestion, Inhalation & Exposure 14.4 End-of-Life, Palliative Care & Organ Donation
15 Professional Caring I — Synergy, Advocacy & Caring
15.1 AACN Synergy Model Overview 15.2 Advocacy & Moral Agency 15.3 Caring Practices & Clinical Inquiry
16 Professional Caring II — Collaboration, Diversity & Systems
16.1 Collaboration, Facilitation of Learning & Response to Diversity 16.2 Systems Thinking
2.3 Cardiac Transplant
Key Takeaways Explain This Topic AI
Pediatric heart transplant indications include end-stage cardiomyopathy, failed single-ventricle palliation, and unresectable tumors—when medical/surgical options are exhausted
Rejection surveillance combines clinical perfusion assessment, echo function, arrhythmia vigilance, and biopsy/noninvasive protocols per transplant center
Immunosuppression commonly includes calcineurin inhibitors, antiproliferative agents, and corticosteroids; nurses own timing, levels, interaction checks, and infection precautions
Infection risk is highest early after transplant and with intensified antirejection therapy; fever may be blunted—trend cultures, viral PCR, and opportunistic pathogen screens
PICU priorities after transplant: graft function, RV afterload (PVR), bleeding/tamponade, denervated-heart pharmacology (atropine ineffective; use direct-acting agents), and meticulous isolation practices
Last updated: July 2026
2.3 Cardiac Transplant
Quick Answer: Pediatric heart transplantation is offered when myocardial failure or anatomy cannot be rehabilitated—commonly dilated cardiomyopathy and failing single-ventricle circulation. Post-transplant PICU care centers on graft systolic/diastolic function, pulmonary vascular resistance facing the donor right ventricle, rejection surveillance, timed immunosuppression with drug-level stewardship, and aggressive infection prevention because fever and inflammatory signs may be muted.
Indications and Listing Context
Heart transplant is considered when survival and quality of life with native heart options are unacceptable. High-yield pediatric indications include:
Dilated cardiomyopathy refractory to medical therapy and unable to wean from inotropes/VAD support
Restrictive or hypertrophic cardiomyopathy with end-stage diastolic failure or ischemia/arrhythmia risk not amenable to other surgery
Failed or failing single-ventricle palliation (e.g., protein-losing enteropathy, plastic bronchitis, systemic ventricular failure after Fontan)
- Complex congenital heart disease without a durable surgical pathway
- Selected unresectable cardiac tumors or irreversible graft failure after prior transplant (retransplant)
Contraindications are center-specific but conceptually include irreversible elevated PVR beyond what a donor right ventricle can face, active uncontrolled infection, and social/adherence barriers that make lifelong immunosuppression unsafe. Mechanical circulatory support (VAD/ECMO) is often a bridge; nursing continuity from bridge to transplant includes device alarms, anticoagulation, and infection control that carry into the post-transplant phase.
Early Postoperative Graft Care
The transplanted heart is denervated . Resting heart rate is often higher; atropine will not reliably increase rate because vagal innervation is absent. Bradycardia and AV block are treated with isoprotenerol, epinephrine, pacing , or other direct-acting chronotropes per protocol—not relying on vagolytic drugs.
Immediate PICU priorities
Priority Focus Notes
Graft systolic function Echo, lactate, mixed venous/NIRS, urine Primary graft dysfunction needs early recognition
- Right ventricular afterload PVR optimization Donor RV may face recipient pulmonary hypertension
- Bleeding / tamponade Chest tubes, equalization of pressures Redo sternotomy risk in congenital patients
- Rhythm Temporary wires, pacing thresholds Denervated response alters drug choices
Immunosuppression start Exact timing and levels Missed doses invite rejection; excess invites infection/toxicity
Strategies that lower PVR—adequate oxygenation, avoidance of acidosis and hypercarbia extremes, sedation, inhaled nitric oxide when indicated—protect the donor RV. Volume loading must be thoughtful: the denervated, ischemic-reperfusion–stressed myocardium may not tolerate overdistension.
Rejection Surveillance
Rejection remains a leading threat to graft survival. Categories include cellular rejection and antibody-mediated rejection; exam questions emphasize recognition and nursing response , not histologic grading minutiae.
Clinical and monitoring clues:
New or worsening heart failure signs: tachycardia beyond baseline denervated rate, gallop, edema, hepatomegaly, feeding intolerance
- Arrhythmias or unexplained low cardiac output
- Echo: reduced ejection fraction, increased wall thickness, new effusion, diastolic dysfunction
Endomyocardial biopsy (scheduled or for-cause) and center-specific noninvasive gene-expression or donor-derived cell-free DNA assays
Nursing role: know the surveillance calendar, protect vascular access for biopsy, watch for post-biopsy complications (tamponade, tricuspid injury, arrhythmia), and escalate subtle perfusion changes rather than waiting for frank shock. Intensified immunosuppression for treated rejection raises infection and drug-toxicity risk—plan isolation and lab monitoring accordingly.
Immunosuppression Nursing
Typical multidrug regimens combine:
Calcineurin inhibitor (tacrolimus or cyclosporine) — nephrotoxicity, tremor, hypertension, drug interactions via CYP3A4
- Antiproliferative agent (mycophenolate or azathioprine) — marrow suppression, GI intolerance
- Corticosteroids — hyperglycemia, wound healing delay, hypertension, mood changes; tapered when possible
Induction agents (ATG, basiliximab, etc.) in many pediatric protocols — profound early lymphodepletion and infection risk
Nursing non-negotiables:
- Administer on schedule; hold parameters only with explicit transplant-team orders tied to trough levels
- Draw troughs correctly timed before doses
Screen for interactions (azole antifungals, macrolides, certain anticonvulsants, grapefruit) that spike or crash calcineurin levels
- Monitor renal function, CBC, glucose, magnesium, and blood pressure
- Educate caregivers early: lifelong adherence prevents late rejection
Never start nephrotoxic or interacting antimicrobials without transplant pharmacy/team clearance.
Infection Risk
Immunosuppression creates a timed vulnerability curve:
Period Dominant risks Nursing emphasis
Early (weeks) Nosocomial bacteria, Candida, wound/mediastinal infection Hand hygiene, line care, early cultures for subtle signs
Intermediate CMV, EBV, other viruses; Pneumocystis (if prophylaxis lapses) Prophylaxis adherence, viral PCR surveillance
Late Community respiratory viruses; opportunistic infections with rejection treatment Vaccination policy per team (avoid live vaccines while heavily suppressed)
Fever may be absent or blunted. Tachycardia, feeding refusal, irritability, rising CRP/procalcitonin, or graft dysfunction can be infection’s first face. CMV disease can present with cytopenias, hepatitis, pneumonitis, or graft dysfunction—know whether the recipient is D+/R− high risk. Strict visitor screening during RSV/influenza seasons protects both graft and child.
Integrating Structure, Surgery, and Transplant on the Exam
Cardiac malformations explain why a child reaches transplant listing; surgery and catheterization chapters explain bridges and complications along the way; transplant content tests whether you can manage a denervated graft under immunosuppression. When a stem mentions Fontan failure, VAD bridge, or primary graft dysfunction, return to perfusion markers, PVR, rejection versus infection differentiation, and drug-level stewardship.
Practical CCRN framing: If the child is blue and ductal-dependent, think PGE1 and mixing. If the child is post-shunt, think Qp:Qs and thrombosis. If the child is post-switch, think coronaries. If the child is post-transplant, think graft function, denervation pharmacology, rejection surveillance, and infection—often simultaneously.